The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.

Abstract

Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metastases. Three randomized, double-blind, controlled phase III trials are ongoing to establish the efficacy and safety of zoledronic acid in the treatment of osteolytic and osteoblastic bone metastases. In one study, 4 mg zoledronic acid is compared with the standard therapy, 90 mg pamidronate, in treatment of osteolytic lesions in patients with breast cancer and multiple myeloma. Two other studies, one in patients with prostate cancer and bone metastases and another in patients with non-small cell lung cancer and other tumor types, are placebo-controlled. The primary end point in all three studies is the frequency of skeletal complications resulting from bone metastases. Adjuvant trials that assess the ability of zoledronic acid to prevent or reduce the incidence of bone metastases in patients at high risk for future skeletal metastasis are also planned or ongoing. The rationale and design of these ongoing and planned studies is discussed.

• Authors: R E Coleman, J J Seaman
• Journal: Seminars in oncology (Semin Oncol) Vol. 28 Issue 2 Suppl 6 Pg. 11-6 (Apr 2001) ISSN: 0093-7754 [Print] United States
• PMID: 11346860 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Diphosphonates
• Imidazoles
• Zoledronic Acid

Topics

• Antineoplastic Agents (therapeutic use)
• Bone Neoplasms (drug therapy, prevention & control, secondary)
• Clinical Trials, Phase III as Topic
• Diphosphonates (therapeutic use)
• Humans
• Imidazoles (therapeutic use)
• Zoledronic Acid